OREX Financial Facts

Net loss: 47.66M
Total revenues: 7M
See Full Income Statement

Deferred revenue, current portion: 2.26M
Total stockholders' equity: 73.42M
See Full Balance Sheet

Orexigen Therapeutics (OREX) Earnings

  |   Expand Research on OREX
Next EPS Date 2/27/17 *Est. EPS Growth Rate +1,344.4% *Last Qtr.
Average EPS % Beat Rate +23.5% Revenue Growth Rate -30.0% *Last Qtr.
Average % Move 1-Wk after EPS -34.8% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/3/16 Q316 $1.12-$2.24 +$3.36$7M$8.17M N/A Details
8/4/16 Q216 -$1.73-$1.47 -$0.26$7.8M$6.88M N/A Details
5/4/16 Q116 -$0.15-$0.17 +$0.02$5M$8.26M N/A Details
2/26/16 Q415 -$0.12-$0.08 -$0.04$4.9M$14.07M N/A Details
11/5/15 Q315 -$0.09-$0.16 +$0.07$10M$12.17M N/A Details
8/6/15 Q215 -$0.18-$0.17 -$0.01$5.2M$4.92M N/A Details
5/8/15 Q115 -$0.14-$0.14 $0.00$4.36M$7.28M N/A Details
2/25/15 Q414 $0.00$0.21 -$0.21$22.95M$49.65M N/A Details